공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

프로테인 키나아제 C-ε(nPKC-ε/EC 2.7.11.13) : 파이프라인 리뷰

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Drugs in Development, 2021

리서치사 Global Markets Direct
발행일 2021년 09월 상품 코드 363123
페이지 정보 영문 69 Pages
가격
US $ 3,500 ₩ 4,191,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,000 ₩ 8,382,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,500 ₩ 12,573,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


프로테인 키나아제 C-ε(nPKC-ε/EC 2.7.11.13) : 파이프라인 리뷰 Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Drugs in Development, 2021
발행일 : 2021년 09월 페이지 정보 : 영문 69 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계 각국에서의 프로테인 키나아제 C-ε(nPKC-ε/EC 2.7.11.13) 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발·출시 최신 동향, 각 임상시험 단계 제품 목록, 주요 기업 개요, 주요 약제 개요, 최신 업계 동향 등의 정보를 전해드립니다.

목차

  • 서론
    • 분석 범위
  • 프로테인 키나아제 C-ε(nPKC-ε/EC 2.7.11.13) 개요
  • 치료제 개발
    • 임상시험 단계별
    • 치료 분야별
    • 증상별
  • 파이프라인 제품 개요
    • 후기 단계 제품
    • 초기 단계 제품
  • 각 기업에서 개발중인 치료제
  • 치료제 평가
    • 단독치료 제품/병용 제품별
    • 작용기서별
    • 투여 방법별
    • 분자 종류별
  • 치료제 개발에 참여하고 있는 기업
    • Hadasit Medical Research Services & Development Ltd
    • VM Discovery, Inc.
  • 약제 개요
    • Bryostatin-1
    • DHACP-6
    • Small Molecule to Activate Epsilon PKC for Ischemic Stroke
    • Small Molecule to Activate Epsilon PKC for Traumatic Brain Injury
    • Small Molecule to Activate PKC Epsilon for Neurology
    • Synthetic Peptide to Inhibit Protein Kinase C for Type 2 Diabetes and Insulin Resistance
    • VMD-1201
    • VMD-2202
  • 개발이 휴지 상태인 제품
  • 개발이 중지된 제품
  • 주목해야 할 최신 동향 및 프레스 릴리스(총 15건)
  • 부록

도표

KSM 16.07.27

List of Tables

List of Tables

  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Indication, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Companies, 2021 (Contd..1)
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Pipeline by BryoLogyx Inc, 2021
  • Pipeline by CHS Pharma Inc, 2021
  • Pipeline by Synaptogenix Inc, 2021
  • Pipeline by VM Discovery Inc, 2021
  • Pipeline by Young Therapeutics LLC, 2021
  • Dormant Projects, 2021
  • Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Top 10 Indications, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Summary:

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Protein kinase C (PKC) is an enzyme belonging to a family of serine- and threonine-specific protein kinases that is activated by calcium and the second messenger diacylglycerol. This kinase showed involvement in many different cellular functions, such as neuron channel activation, apoptosis, cardioprotection from ischemia, heat shock response, as well as insulin exocytosis.

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) pipeline Target constitutes close to 11 molecules.The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 9 and 1 respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Genetic Disorders, Infectious Disease, Oncology and Ophthalmology which include indications Alzheimer's Disease, Ischemia Reperfusion Injury, Traumatic Brain Injury, Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Alcohol Addiction, Depression, Dry (Atrophic) Macular Degeneration, Fragile X Syndrome, Human Immunodeficiency Virus (HIV) Infections (AIDS), Ischemic Stroke, Lymphoma, Multiple Sclerosis, Neurology, Parkinson's Disease, Pervasive Developmental Disorder (PDD), Rett Syndrome and Stroke.

The latest report Protein Kinase C Epsilon Type - Drugs In Development, 2021, outlays comprehensive information on the Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13)
  • The report reviews Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Overview
  • Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Companies Involved in Therapeutics Development
  • BryoLogyx Inc
  • CHS Pharma Inc
  • Synaptogenix Inc
  • VM Discovery Inc
  • Young Therapeutics LLC
  • Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Drug Profiles
  • Bryostatin-1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Activate Epsilon PKC for Ischemic Stroke - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Activate Epsilon PKC for Traumatic Brain Injury - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Activate PKC Epsilon for Neurology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Activate PKC Epsilon for Pervasive Developmental Disorder - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Activate PRKCE for Alzheimer's Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit PRKCE for HIV and Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • sulindac - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VMD-2202 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • YT-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • YT-002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Dormant Products
  • Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Discontinued Products
  • Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Product Development Milestones
  • Featured News & Press Releases
  • Jul 26, 2021: Synaptogenix discloses positive results of further Bryostatin trial analyses in presentation at Alzheimer's Association International Conference 2021
  • Jul 14, 2021: Synaptogenix to present data at Alzheimer's Association International Conference 2021 Highlighting Bryostatin Restores Cognitive Function Above Baseline
  • Jul 07, 2021: Synaptogenix announces regenerative patent award to treat Alzheimer's disease
  • Jun 09, 2021: Synaptogenix announces phase 2b NIH sponsored Alzheimer's disease trial update
  • Apr 01, 2021: Synaptogenix announces phase 2b Bryostatin-1 clinical trial update
  • Feb 04, 2021: Synthetic bryostatin available to expand neurodegenerative indication trials
  • Oct 13, 2020: BryoLogyx announces completion of world's first GMP synthesis of bryostatin-1
  • Oct 07, 2020: Neurotrope begins Phase II trial of Alzheimer's drug candidate
  • Aug 04, 2020: BryoLogyx announces cooperative research and development agreement for Bryostatin-1 with National Cancer Institute
  • Jul 30, 2020: Neurotrope Bioscience announces agreement with worldwide clinical trials, to conduct ongoing phase 2 study of Bryostatin-1, partially funded by NIH, for Alzheimer's Disease
  • Jun 10, 2020: Neurotrope announces strategic partnership with BryoLogyx for supply of synthetic Bryostatin-1 and continuation of the National Cancer Institute (NCI) trial for childhood leukemia
  • May 28, 2020: Neurotrope launches new long-term clinical trial of Bryostatin with the National Institutes of Health for the treatment of patients with Alzheimer's Disease
  • Jan 22, 2020: Neurotrope provides corporate update after completing Bryostatin-1 data analysis for advanced Alzheimer's disease trial
  • Sep 10, 2019: Neurotrope Alzheimer's Phase II trial fails to meet endpoints
  • Aug 13, 2019: Neurotrope announces publication highlighting the potential of bryostatin as a unique neurorestorative therapy
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q